Cervomed INC 10-Q quarterly reports

CervoMed Inc. reported Q2 2026 results, highlighting successful financings totaling $20.5 million and a patent allowance, while continuing to advance its lead drug candidate, neflamapimod, for age-related brain disorders.

CervoMed Inc. reported a wider net loss for Q1 2026 due to decreased grant revenue and increased operating expenses, while cash reserves remain a concern for continued operations.

CervoMed Inc. reported increased net losses and significant cash burn in Q3 2025, alongside positive Phase 2b neflamapimod data for DLB and FDA alignment for a pivotal Phase 3 trial, while facing substantial doubt about its ability to continue as a going concern.

CervoMed Inc. reports increased net losses and cash burn in Q2 2025, while its lead drug candidate neflamapimod shows promising clinical results in ongoing trials for neurodegenerative disorders.

CervoMed Inc. announces its Q1 2025 financial results, highlighting a net loss of $4.9 million and provides updates on its ongoing clinical trials, including positive 16-week extension data from the RewinD-LB Trial.

CervoMed Inc. announced its Q3 2024 financial results, highlighting progress in its clinical trials and financial position.

CervoMed Inc. announced its Q2 2024 financial results and the completion of enrollment in its Phase 2b RewinD-LB trial for Early-Stage DLB.

CervoMed Inc. reported a net loss of $2.5 million for the first quarter of 2024, while highlighting progress in its clinical trials and a recent $50 million private placement.